Analysis of cytogenetic alterations in  asthmatic patients treated with beclometasone dipropionate

A. Lintsov (St.Petersburg, Russian Federation), B. Uslontsev (St.Petersburg, Russian Federation), N. Pleskach (St.Petersburg, Russian Federation), V. Mikhelson (St.Petersburg, Russian Federation)

Source: International Congress 2018 – New developments in the treatment of asthma
Session: New developments in the treatment of asthma
Session type: Thematic Poster
Number: 1040
Disease area: Airway diseases

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
A. Lintsov (St.Petersburg, Russian Federation), B. Uslontsev (St.Petersburg, Russian Federation), N. Pleskach (St.Petersburg, Russian Federation), V. Mikhelson (St.Petersburg, Russian Federation). Analysis of cytogenetic alterations in  asthmatic patients treated with beclometasone dipropionate. 1040

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Comparative clinical study of addition theophylline to low-dose inhaled beclomethasone dipropionate and medium-dose inhaled beclomethasone dipropionate in patients with mild-to-moderate persistent asthma
Source: Eur Respir J 2001; 18: Suppl. 33, 98s
Year: 2001

Salmeterol and beclomethasone dipropionate versus higher dose beclomethasone dipropionate in asthma patients
Source: Eur Respir J 2005; 26: Suppl. 49, 124s
Year: 2005

Vascular remodelling and inhaled beclomethasone dipropionate in COPD patients
Source: Eur Respir J 2007; 30: Suppl. 51, 598s
Year: 2007

Effects of the changing from chlorofluorocarbon (CFC)- beclomethasone dipropionate (BDP) to hydrofluoroalkane (HFA)-BDP on pulmonary function in asthmatic children
Source: Annual Congress 2007 - Anti-inflammatory therapy for childhood asthma
Year: 2007


Clinical efficacy of seretide and beclomethasone dipropionate in patients with corticosteroid-dependent bronchial asthma and quality of life
Source: Eur Respir J 2004; 24: Suppl. 48, 285s
Year: 2004

HFA beclomethasone dipropionate (HFA-BDP) extrafine aerosol and formoterol in optimizing the management of bronchial asthma at children
Source: Eur Respir J 2005; 26: Suppl. 49, 159s
Year: 2005

Inhalation of beclomethason dipropionate spray compared with theophilline as primary treatment for chronic mild-to-moderate asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 42s
Year: 2002

Protective effect of inhaled beclomethasone dipropionate (BDP) in asthmatic patients with exercise-induced bronchoconstriction (EIB)
Source: Eur Respir J 2002; 20: Suppl. 38, 306s
Year: 2002

Bronchoprotective and anti-inflammatory effect of beclometasone dipropionate plus formoterol HFA fixed combination in asthmatic patients
Source: Annual Congress 2009 - Aspects of uncontrolled asthma
Year: 2009

A pharmaco-epidemiological audit of beclomethasone dipropionate extrafine aerosol in patients with asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 471s
Year: 2002

HFA vs CFC beclomethasone dipropionate – comparative effectiveness in asthma management
Source: Eur Respir J 2006; 28: Suppl. 50, 498s
Year: 2006

Comparison of a new extrafine beclomethasone dipropionate HFA134a-formulated pMDI with a standard BDP CFC pMDI in adults with moderate persistent asthma
Source: Eur Respir J 2006; 28: Suppl. 50, 206s
Year: 2006

Effects of inhaled corticosteroids on growth in asthmatic children: A comparision of fluticasone propianate with budesonide
Source: Eur Respir J 2003; 22: Suppl. 45, 133s
Year: 2003

Therapeutic equivalence of beclomethasone dipropionate/formoterol administered via NEXTTM DPI with beclomethasone dipropionate/formoterol administered via HFA pMDI in adult asthmatic patients
Source: Annual Congress 2010 - Drug delivery and pharmacokinetics II
Year: 2010

Lung deposition of the extrafine dry powder fixed combination beclomethasone dipropionate plus formoterol fumarate via the NEXT DPI® in healthy subjects, asthmatic and COPD patients
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics I
Year: 2011

Comparison of medium dose inhaled beclomethasone dipropionate (BDP) and low dose inhaled BDP plus sustained-release theophylline in the treatment of patients with moderate persistent asthma
Source: Eur Respir J 2002; 20: Suppl. 38, 42s
Year: 2002

Nebulized beclomethasone dipropionate is as effective and as well tolerated than nebulized budesonide to prevent asthma exacerbations in infants
Source: Eur Respir J 2001; 18: Suppl. 33, 122s
Year: 2001

Once daily nebulized beclomethasone in asthmatic children
Source: Eur Respir J 2005; 26: Suppl. 49, 159s
Year: 2005

Efficacy, safety and cost of using beclomethason dipropionate in patients with persistent moderate bronchial asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 124s
Year: 2004

Systemic activity of inhaled beclomethasone dipropionate HFA: a comparison of volume spacers
Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues
Year: 2009